Last reviewed · How we verify
B&L ReNu MultiPlus™ — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
B&L ReNu MultiPlus™ (B&L ReNu MultiPlus™) — University of Waterloo.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| B&L ReNu MultiPlus™ TARGET | B&L ReNu MultiPlus™ | University of Waterloo | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- B&L ReNu MultiPlus™ CI watch — RSS
- B&L ReNu MultiPlus™ CI watch — Atom
- B&L ReNu MultiPlus™ CI watch — JSON
- B&L ReNu MultiPlus™ alone — RSS
Cite this brief
Drug Landscape (2026). B&L ReNu MultiPlus™ — Competitive Intelligence Brief. https://druglandscape.com/ci/b-l-renu-multiplus. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab